hit counter
Alimera Sciences, Inc. (ALIM) Stock News Sentiment & Price - Sentifly
ALIM - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Alimera Sciences, Inc. (ALIM)

USA
Drug Manufacturers - Major
NASDAQ
ALIM Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ALIM Latest news
GlobeNewsWire
Neutral
Alimera Sciences to Participate in Upcoming November 2021 Investor Conferences
2021-11-09 13:16

ATLANTA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that Rick Eiswirth, Alimera's President and Chief Executive Officer, will participate in three investor conference events in November.

Seeking Alpha
Neutral
Alimera Sciences, Inc. (ALIM) CEO Richard Eiswirth on Q3 2021 Results - Earnings Call Transcript
2021-10-28 12:56

Alimera Sciences, Inc. (ALIM) CEO Richard Eiswirth on Q3 2021 Results - Earnings Call Transcript

Zacks Investment Research
Negative
Alimera Sciences (ALIM) Reports Q3 Loss, Misses Revenue Estimates
2021-10-28 09:56

Alimera Sciences (ALIM) delivered earnings and revenue surprises of -15.38% and -1.20%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire
Neutral
Alimera Sciences Announces Third Quarter 2021 Financial Results
2021-10-28 07:30

ATLANTA, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the third quarter of 2021. Alimera will host a conference call today at 9:00 a.m. EDT to discuss these results.

GlobeNewsWire
Neutral
Alimera Sciences to Report Third Quarter 2021 Financial Results on Thursday, October 28, 2021, and Provide Corporate Update
2021-10-21 08:00

Conference Call to be held Thursday, October 28, 2021, at 9:00am Eastern Time Conference Call to be held Thursday, October 28, 2021, at 9:00am Eastern Time

Zacks Investment Research
Negative
Analysts Estimate Alimera Sciences (ALIM) to Report a Decline in Earnings: What to Look Out for
2021-10-20 16:16

Alimera Sciences (ALIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Pulse2
Positive
ALIM Stock: Why It Increased Today
2021-10-13 21:14

The stock price of Alimera Sciences Inc (NASDAQ: ALIM) increased by over 6% today. This is why it happened.

GlobeNewsWire
Neutral
Recent 24-Month Real-World PALADIN Data Demonstrate the Ability of ILUVIEN® to Significantly Reduce Treatment Burden in Patients with Diabetic Macular Edema
2021-10-13 08:00

PALADIN Study Data Presented at the American Society of Retina Specialists Shows That Post-ILUVIEN, the Percentage of Eyes Receiving One Yearly Treatment or Less Increased 3.2-Fold Compared to Pre-ILUVIEN

GlobeNewsWire
Neutral
Alimera Sciences, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference
2021-09-02 16:30

ATLANTA, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer., announces today that Chief Executive Officer Rick Eiswirth will present at the 23rd Annual H.C. Wainwright Global Investment Conference which is being held virtually from September 13 – 15, 2021.

GlobeNewsWire
Neutral
Alimera Sciences Announces National Pricing and Reimbursement Granted for ILUVIEN® for DME in Belgium
2021-08-24 08:00

ATLANTA, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, announces that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, received pricing and reimbursement approval for ILUVIEN® for diabetic macular edema (DME) in Belgium from the National Institute for Health and Disability Insurance (INAMI). Pricing and reimbursement approval was sought and secured by Alimera's distribution partner in France and the Benelux region, Horus Pharma S.A.S. (Horus). Horus is currently in the launch phase in Belgium.

Loading more news...